Cancer research priorities and gaps in Iran: the influence of cancer burden on cancer research outputs between 1997 and 2014

Public Health

Volumn 144, Issue , 2017, Pages 42-47

  Majidi, A ^a   Salimzadeh, H ^a   Beiki, O ^b,c   Delavari, F ^a   Majidi, S ^d   Delavari, A ^a   Malekzadeh, R ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cancer burden; Cancer research; Iran; Priority setting; Research priorities

Indexed keywords

CANCER; DISABILITY; MEDICINE; PUBLIC HEALTH; RESEARCH WORK;

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RESEARCH; CONTROLLED STUDY; HUMAN; IRAN; LEUKEMIA; MAJOR CLINICAL STUDY; MORTALITY RATE; QUALITY ADJUSTED LIFE YEAR; STOMACH CANCER; TUMOR VOLUME; COST OF ILLNESS; DISABLED PERSON; EPIDEMIOLOGY; ETHNOLOGY; EVALUATION STUDY; FEMALE; GLOBAL DISEASE BURDEN; MALE; MORTALITY; NEOPLASM; REGRESSION ANALYSIS; RESEARCH; STATISTICS AND NUMERICAL DATA; TRENDS;

IRAN;

COST OF ILLNESS; DISABLED PERSONS; FEMALE; GLOBAL BURDEN OF DISEASE; HUMANS; IRAN; MALE; NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; REGRESSION ANALYSIS; RESEARCH;

EID: 85007433756     PISSN: 00333506     EISSN: 14765616     Source Type: Journal    
DOI: 10.1016/j.puhe.2016.11.002     Document Type: Article

References (27)

1. 1 Mousavi, S.M., Gouya, M.M., Ramazani, R., Davanlou, M., Hajsadeghi, N., Seddighi, Z., Cancer incidence and mortality in Iran. Ann Oncol 20 (2009), 556–563.
2. 2 GLOBOCAN, Estimated cancer incidence, mortality and prevalence worldwide in 2012. 2012.
3. 3 Beaglehole, R., Bonita, R., Alleyne, G., Horton, R., Li, L., Lincoln, P., et al. UN high-level meeting on non-communicable diseases: addressing four questions. Lancet 378 (2011), 449–455.
4. 4 Implementation research in health: a practical guide, 2013.
5. 5 Chalmers, I., Bracken, M.B., Djulbegovic, B., Garattini, S., Grant, J., Gülmezoglu, A.M., et al. How to increase value and reduce waste when research priorities are set. Lancet 383 (2014), 156–165.
6. 6 Murray, C.J., Ezzati, M., Flaxman, A.D., Lim, S., Lozano, R., Michaud, C., et al. GBD 2010: design, definitions, and metrics. Lancet 380 (2013), 2063–2066.
7. 7 Lopez, A.D., Mathers, C.D., Ezzati, M., Jamison, D.T., Murray, C.J., Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367 (2006), 1747–1757.
8. 8 Shibuya, K., Mathers, C.D., Boschi-Pinto, C., Lopez, A.D., Murray, C.J., Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer, 2, 2002, 37.
9. 9 Fitzmaurice, C., Dicker, D., Pain, A., Hamavid, H., Moradi-Lakeh, M., MacIntyre, M.F., et al. The Global Burden of Cancer 2013. JAMA Oncol 1 (2015), 505–527.
10. 10 Gwatkin, D.R., Global burden of disease. Lancet, 350, 1997, 141.
11. 11 Metrics IfH, Evaluation, Global Burden of Disease (GBD). Inst Health Metrics Eval, 2013 [cited 2015]; Available from: http://www.healthdata.org/.
12. 12 Mathers, C., Fat, D.M., Boerma, J.T., The global burden of disease: 2004 update. 2008, World Health Organization.
13. 13 Babaei, M., Pourfarzi, F., Yazdanbod, A., Chiniforush, M.M., Derakhshan, M.H., Mousavi, S.M., et al. Gastric cancer in Ardabil, Iran—a review and update on cancer registry data. Asian Pac J Cancer Prev 11 (2010), 595–599.
14. 14 Lewison, G., Definition of cancer research: journals, titles, abstracts or keywords?. DESIDOC J Libr Inf Technol, 31, 2011.
15. 15 Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., et al. GLOBOCAN 2012 v1. 0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [internet]. 2013, International Agency for Research on Cancer, Lyon globocan iarc fr (accessed 10 October 2014).
16. 16 DeSantis, C., Siegel, R., Bandi, P., Jemal, A., Breast cancer statistics, 2011. CA Cancer J Clin 61 (2011), 408–418.
17. 17 Sullivan, R., Badwe, R.A., Rath, G.K., Pramesh, C., Shanta, V., Digumarti, R., et al. Cancer research in India: national priorities, global results. Lancet Oncol 15 (2014), e213–e222.
18. 18 WHO, Cancer control early detection-WHO guide for effective programmes. 2007, World Health Organization.
19. 19 Azadeh, S., Reza, F.S., Sara, A., Mohsen, V., Bijan, M.-D., Zali, Z.R., Four years incidence rate of colorectal cancer in Iran: a survey of national cancer registry data-implications for screening. Asian Pac J Cancer Prev 13 (2012), 2695–2698.
20. 20 Fock, K.M., Ang, T.L., Epidemiology of Helicobacter pylori infection and gastric cancer in Asia. J Gastroenterol Hepatol 25 (2010), 479–486.
21. 21 Singh, K., Ghoshal, U.C., Causal role of Helicobacter pylori infection in gastric cancer: an Asian enigma. World J Gastroenterol, 12, 2006, 1346.
22. 22 Fock, K.M., Talley, N., Moayyedi, P., Hunt, R., Azuma, T., Sugano, K., et al. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 23 (2008), 351–365.
23. 23 Hongo, M., Nagasaki, Y., Shoji, T., Epidemiology of esophageal cancer: orient to occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol 24 (2009), 729–735.
24. 24 Bertuccio, P., Chatenoud, L., Levi, F., Praud, D., Ferlay, J., Negri, E., et al. Recent patterns in gastric cancer: a global overview. Int J Cancer 125 (2009), 666–673.
25. 25 Marzban, M., Nahvijou, A., Jafari, N., Six-fold difference in the stomach cancer mortality rate between northern and southern Iran. Arch Iran Med, 15, 2012, 741.
26. 26 Malekzadeh, R., Derakhshan, M.H., Malekzadeh, Z., Gastric cancer in Iran: epidemiology and risk factors. Arch Iran Med 12 (2009), 576–583.
27. 27 Majidi, A., Ghiasvand, R., Hadji, M., Nahvijou, A., Mousavi, A.-S., Pakgohar, M., et al. Priority setting for improvement of cervical Cancer prevention in Iran. Int J Health Policy Manag 5 (2016), 225–232.